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Background: CRP, a marker of inflammation, may help in the detection of patients at increased risk for CVD. The TNT study showed that intensive 
therapy with atorvastatin (ATV) 80 mg provides significant clinical benefit beyond that afforded by treatment with ATV 10 mg over 4.9 years of follow-
up in stable CHD patients. This post-hoc nested case-control substudy investigated the value of CRP levels in the prediction of major cardiovascular 
events (MCVE).
Methods: Initial CRP levels were measured at the time of randomization (following an 8-week ATV 10 mg run-in period).Analyses were conducted 
on blood samples taken from 506 of the 982 patients who experienced a MCVE, and 1012 control patients without events.
Results: Median CRP levels at randomization were 1.77 mg/L for ATV 80 mg and 1.64 mg/L for ATV 10 mg. After 1 year of treatment, CRP levels 
were reduced by 21% and 19%, respectively. Higher baseline CRP was associated with a significant increase in risk of an MCVE in the ATV 10 mg 
group (Table). In the ATV 80 mg group, CRP at randomization had no predictive value for MCVE. The interaction test for treatment and baseline CRP 
level at randomization was not significant (P=0.107). These findings held true following adjustment for age and gender.
Conclusion: CRP was predictive of increased CV risk among patients receiving ATV 10 mg but not for those on ATV 80 mg. These results strongly 
suggest that in patients with stable CHD, intensive lipid-lowering therapy may reduce the risk of MCVE associated with elevated CRP levels.
ATV 80 mg ATV 10 mg
HR 95% CI P HR 95% CI P
Unadjusted 0.99 0.92, 1.06 0.759 1.08 1.02, 1.15 0.015
Adjusted* 0.99 0.92, 1.07 0.817 1.07 1.01, 1.14 0.024
*Adjusted for age and gender
